Literature DB >> 31243002

Reducing minimal residual disease with blinatumomab prior to HCT for pediatric patients with acute lymphoblastic leukemia.

Amy K Keating1, Nathan Gossai2, Christine L Phillips3,4, Kelly Maloney1, Kristen Campbell1, Andrew Doan5, Deepa Bhojwani6, Michael J Burke6, Michael R Verneris1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31243002      PMCID： PMC6616259          DOI： 10.1182/bloodadvances.2018025726

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  17 in total

Review 1.  Minimal residual disease-guided therapy in childhood acute lymphoblastic leukemia.

Authors:  Dario Campana; Ching-Hon Pui
Journal:  Blood       Date:  2017-02-06       Impact factor: 22.113

2.  Blinatumomab for Acute Lymphoblastic Leukemia.

Authors:  Hagop Kantarjian; Elias Jabbour; Max S Topp
Journal:  N Engl J Med       Date:  2017-06-08       Impact factor: 91.245

Review 3.  Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer.

Authors:  Julia Stieglmaier; Jonathan Benjamin; Dirk Nagorsen
Journal:  Expert Opin Biol Ther       Date:  2015-05-13       Impact factor: 4.388

4.  Potential niche indications for blinatumomab as a bridge to hematopoietic cell transplantation.

Authors:  Yi Zeng; Emmanuel Katsanis
Journal:  Bone Marrow Transplant       Date:  2017-09-18       Impact factor: 5.483

5.  Health-related quality of life in adults with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab.

Authors:  Max S Topp; Zachary Zimmerman; Paul Cannell; Hervé Dombret; Johan Maertens; Anthony Stein; Janet Franklin; Qui Tran; Ze Cong; Andre C Schuh
Journal:  Blood       Date:  2018-05-08       Impact factor: 22.113

6.  Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia.

Authors:  Max S Topp; Nicola Gökbuget; Gerhard Zugmaier; Petra Klappers; Matthias Stelljes; Svenja Neumann; Andreas Viardot; Reinhard Marks; Helmut Diedrich; Christoph Faul; Albrecht Reichle; Heinz-August Horst; Monika Brüggemann; Dorothea Wessiepe; Chris Holland; Shilpa Alekar; Noemi Mergen; Hermann Einsele; Dieter Hoelzer; Ralf C Bargou
Journal:  J Clin Oncol       Date:  2014-11-10       Impact factor: 44.544

7.  Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia.

Authors:  Arend von Stackelberg; Franco Locatelli; Gerhard Zugmaier; Rupert Handgretinger; Tanya M Trippett; Carmelo Rizzari; Peter Bader; Maureen M O'Brien; Benoît Brethon; Deepa Bhojwani; Paul Gerhardt Schlegel; Arndt Borkhardt; Susan R Rheingold; Todd Michael Cooper; Christian M Zwaan; Phillip Barnette; Chiara Messina; Gérard Michel; Steven G DuBois; Kuolung Hu; Min Zhu; James A Whitlock; Lia Gore
Journal:  J Clin Oncol       Date:  2016-10-31       Impact factor: 44.544

Review 8.  Blinatumomab, a Bi-Specific Anti-CD19/CD3 BiTE(®) Antibody for the Treatment of Acute Lymphoblastic Leukemia: Perspectives and Current Pediatric Applications.

Authors:  Lindsey M Hoffman; Lia Gore
Journal:  Front Oncol       Date:  2014-03-31       Impact factor: 6.244

9.  Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with Response-Adapted therapy.

Authors:  C-H Pui; D Pei; S C Raimondi; E Coustan-Smith; S Jeha; C Cheng; W P Bowman; J T Sandlund; R C Ribeiro; J E Rubnitz; H Inaba; T A Gruber; W H Leung; J J Yang; J R Downing; W E Evans; M V Relling; D Campana
Journal:  Leukemia       Date:  2016-08-18       Impact factor: 11.528

10.  Management of important adverse events associated with inotuzumab ozogamicin: expert panel review.

Authors:  Partow Kebriaei; Corey Cutler; Marcos de Lima; Sergio Giralt; Stephanie J Lee; David Marks; Akil Merchant; Wendy Stock; Koen van Besien; Matthias Stelljes
Journal:  Bone Marrow Transplant       Date:  2018-01-12       Impact factor: 5.483
View more
  13 in total

1.  Measurable residual disease affects allogeneic hematopoietic cell transplantation in Ph+ ALL during both CR1 and CR2.

Authors:  Satoshi Nishiwaki; Yu Akahoshi; Shuichi Mizuta; Akihito Shinohara; Shigeki Hirabayashi; Yuma Noguchi; Takahiro Fukuda; Naoyuki Uchida; Masatsugu Tanaka; Makoto Onizuka; Yukiyasu Ozawa; Shuichi Ota; Souichi Shiratori; Yasushi Onishi; Yoshinobu Kanda; Masashi Sawa; Junji Tanaka; Yoshiko Atsuta; Shinichi Kako
Journal:  Blood Adv       Date:  2021-01-26

2.  MRD in adult Ph/BCR-ABL-negative ALL: how best to eradicate?

Authors:  Nicola Gökbuget
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

3.  Targeting pediatric leukemia-propagating cells with anti-CD200 antibody therapy.

Authors:  Paraskevi Diamanti; Charlotte V Cox; Benjamin C Ede; Robert A Uger; John P Moppett; Allison Blair
Journal:  Blood Adv       Date:  2021-09-28

4.  Outcomes of Allogeneic Hematopoietic Cell Transplantation after Salvage Therapy with Blinatumomab in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia.

Authors:  Amandeep Salhotra; Dongyun Yang; Sally Mokhtari; Monzr M Al Malki; Haris Ali; Karamjeet S Sandhu; Ahmed Aribi; Samer Khaled; Matthew Mei; Elizabeth Budde; David Snyder; Thai Cao; Ricardo Spielberger; Guido Marcucci; Vinod Pullarkat; Stephen J Forman; Ryotaro Nakamura; Anthony Stein; Ibrahim Aldoss
Journal:  Biol Blood Marrow Transplant       Date:  2020-02-05       Impact factor: 5.609

Review 5.  Chimeric Antigen Receptor-Modified T Cells and T Cell-Engaging Bispecific Antibodies: Different Tools for the Same Job.

Authors:  Melanie Schwerdtfeger; Mohamed-Reda Benmebarek; Stefan Endres; Marion Subklewe; Vincenzo Desiderio; Sebastian Kobold
Journal:  Curr Hematol Malig Rep       Date:  2021-04-30       Impact factor: 3.952

Review 6.  Bispecific Antibodies and Other Non-CAR Targeted Therapies and HSCT: Decreased Toxicity for Better Transplant Outcome in Paediatric ALL?

Authors:  Krisztián Miklós Kállay; Mattia Algeri; Jochen Buechner; Aviva C Krauss
Journal:  Front Pediatr       Date:  2022-02-02       Impact factor: 3.418

Review 7.  Acute Lymphoblastic Leukaemia in the Youngest: Haematopoietic Stem Cell Transplantation and Beyond.

Authors:  Adriana Balduzzi; Jochen Buechner; Marianne Ifversen; Jean-Hugues Dalle; Anca M Colita; Marc Bierings
Journal:  Front Pediatr       Date:  2022-02-24       Impact factor: 3.418

8.  Clinical utilization of blinatumomab and inotuzumab immunotherapy in children with relapsed or refractory B-acute lymphoblastic leukemia.

Authors:  Cristina F Contreras; Christine S Higham; Astrid Behnert; Kailyn Kim; Elliot Stieglitz; Sarah K Tasian
Journal:  Pediatr Blood Cancer       Date:  2020-10-24       Impact factor: 3.167

Review 9.  Personalized therapy in pediatric high-risk B-cell acute lymphoblastic leukemia.

Authors:  Seth E Karol; Ching-Hon Pui
Journal:  Ther Adv Hematol       Date:  2020-06-02

10.  In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo.

Authors:  N N Parayath; S B Stephan; A L Koehne; P S Nelson; M T Stephan
Journal:  Nat Commun       Date:  2020-11-27       Impact factor: 14.919
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.